Abstract P1-02-03: Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin

e11537 Background: In a few number of studies a possible relationship between inflammatory markers and the prognosis, chemotherapy response and survival in breast cancer has been reported. The aim of this study is to point out the place of serum markers as a prognostic factor in early stage breast cancer. Methods: This study was conducted in Hacettepe University Cancer Institute. Patients operated and stage IA to III C for breast cancer between December 2009 and June 2012 were included the study. Before the any adjuvant therapy inflammation markers were studied. Results: A total of 704 patients were included in the study. The median age of the patients was 50 (25-92). 42,8% of the patients were premenopausal and 48,2% postmenopausal. The median follow up period for the whole study group was 22 months (3-287). We studied the CRP, erythrocyte sedimentation rate, B2 microglobulin, LDH, albumin, and ferritin studied and values for each marker were grouped as high and normal. There was no statistically significant difference in disease free survival and overall survival for each marker who had high and normal levels. Conclusions: We did not found any inflammatory markers as a prognostic value. However our follow up time is short and we should be wait for more mature data.

Download Full-text

Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status

Breast Cancer Research and Treatment ◽

10.1023/a:1006405504158 ◽

2000 ◽

Vol 60 (3) ◽

pp. 227-234 ◽

Cited By ~ 43

Author(s):

James L. McCoy ◽

Ruth Rucker ◽

John A. Petros

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Lymph Node Status ◽

Cell Mediated Immunity ◽

Tumor Associated Antigens ◽

Node Status

Download Full-text

Serum Analysis of Women with Early-Stage Breast Cancer Using a Mini-Array of Tumor-Associated Antigens

Biosensors ◽

10.3390/bios10100149 ◽

2020 ◽

Vol 10 (10) ◽

pp. 149

Author(s):

Alma Oaxaca-Camacho ◽

Oscar Ochoa-Mojica ◽

Adriana Aguilar-Lemarroy ◽

Luis Jave-Suárez ◽

José Muñoz-Valle ◽

...

Keyword(s):

Breast Cancer ◽

Triosephosphate Isomerase ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Antibody Detection ◽

Dot Blot ◽

Tumor Associated Antigens ◽

Patients With Cancer ◽

Positive Antibody ◽

Alpha 1 Antitrypsin

Background: Several studies have shown that patients with cancer have antibodies in serum that react with cellular autoantigens, known as Tumor-Associated Antigens (TAA). The present work aimed to determine whether a mini-array comprising four recombinant TAA increases the detection of specific serum antibodies for the diagnosis of early-stage breast cancer. Methods: The mini-array included Alpha 1-AntiTrypsin (A1AT), TriosePhosphate Isomerase 1 (TPI1), Peptidyl-Prolyl cis-trans Isomerase A (PPIA), and PeroxiReDoXin 2 (PRDX2) full-length recombinant proteins. The proteins were produced after gene cloning, expression, and purification, and were verified by Western blot assays. Then, Dot-Blot was performed to find antibodies against the four TAA in 12 sera from women with early-stage breast cancer (stage II) and 12 sera from healthy women. Results: Antibody detection against individual TAA in early-stage breast cancer sera ranged from 58.3% to 83.3%. However, evaluation of the four TAA showed that there was a positive antibody reaction reaching a sensitivity of 100% and a specificity of 85% in early-stage breast cancer, suggesting that this mini-array must be evaluated as a clinical diagnostic tool for early-stage breast cancer in a larger sample size. Conclusion: Our results suggest that TAA mini-arrays may provide a promising and powerful method for improving the detection of breast cancer in Mexican women.

Download Full-text